Can-Fite BioPharma Ltd.
Business
Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small-molecule therapeutics that selectively target the A3 adenosine receptor to treat cancer, liver and inflammatory diseases and erectile dysfunction. Its main product candidates include CF101 (Piclidenoson), CF102 (Namodenoson) and CF602, alongside a commercial A3AR predictive biomarker test and related preclinical compounds. The company’s operations focus on clinical development, in-licensing/out-licensing, third‑party manufacturing and commercialization partnerships. It pursues global clinical trials and commercial partnerships across North America, Europe and Asia, relying on regional distributors and CROs for development and market access.
Summary from filing dated 2025-04-14
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $405.0K |
| Net income | $-9.83M |
| Total assets | $9.51M |
| Total liabilities | — |
| Stockholders' equity | $5.59M |
| Operating cash flow | $-8.95M |